Literature DB >> 32467324

Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.

Camille Jacqueline1, Amanda Lee2, Nolan Frey2, Jonathan S Minden2, Olivera J Finn3.   

Abstract

Tumor-associated antigens (TAA) are self-molecules abnormally expressed on tumor cells, which elicit humoral and cellular immunity and are targets of immunosurveillance. Immunity to TAAs is found in some healthy individuals with no history of cancer and correlates positively with a history of acute inflammatory and infectious events and cancer risk reduction. This suggests a potential role in cancer immunosurveillance for the immune memory elicited against disease-associated antigens (DAA) expressed on infected and inflamed tissues that are later recognized on tumors as TAAs. To understand probable sources for DAA generation, we investigated in vitro the role of inflammation that accompanies both infection and carcinogenesis. After exposure of normal primary breast epithelial cells to proinflammatory cytokines IL1β, IL6, and TNFα, or macrophages producing these cytokines, we saw transient overexpression of well-known TAAs, carcinoembryonic antigen and Her-2/neu, and overexpression and hypoglycosylation of MUC1. We documented inflammation-induced changes in the global cellular proteome by 2D difference gel electrophoresis combined with mass spectrometry and identified seven new DAAs. Through gene profiling, we showed that the cytokine treatment activated NF-κB and transcription of the identified DAAs. We tested three in vitro-identified DAAs, Serpin B1, S100A9, and SOD2, and found them overexpressed in premalignant and malignant breast tissues as well as in inflammatory conditions of the colon, stomach, and liver. This new category of TAAs, which are also DAAs, represent a potentially large number of predictable, shared, immunogenic, and safe antigens to use in preventative cancer vaccines and as targets for cancer therapies. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32467324      PMCID: PMC7415557          DOI: 10.1158/2326-6066.CIR-19-0870

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  64 in total

Review 1.  MUC1 immunobiology: from discovery to clinical applications.

Authors:  Anda M Vlad; Jessica C Kettel; Nehad M Alajez; Casey A Carlos; Olivera J Finn
Journal:  Adv Immunol       Date:  2004       Impact factor: 3.543

Review 2.  Crosstalk of reactive oxygen species and NF-κB signaling.

Authors:  Michael J Morgan; Zheng-gang Liu
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

Review 4.  Human Tumor Antigens Yesterday, Today, and Tomorrow.

Authors:  Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2017-05       Impact factor: 11.151

Review 5.  Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.

Authors:  Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2014-08       Impact factor: 11.151

6.  Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer.

Authors:  Michael Kvorjak; Yasmine Ahmed; Michelle L Miller; Raahul Sriram; Claudia Coronnello; Jana G Hashash; Douglas J Hartman; Cheryl A Telmer; Natasa Miskov-Zivanov; Olivera J Finn; Sandra Cascio
Journal:  Cancer Immunol Res       Date:  2019-12-12       Impact factor: 11.151

7.  Mechanism of plasminogen activator inhibitor-1 regulation by oncostatin M and interleukin-1 in human astrocytes.

Authors:  Aneta Kasza; Daniel L Kiss; Sunita Gopalan; Weili Xu; Russell E Rydel; Aleksander Koj; Tomasz Kordula
Journal:  J Neurochem       Date:  2002-11       Impact factor: 5.372

8.  Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.

Authors:  Yingbo Shao; Xianfu Sun; Yaning He; Chaojun Liu; Hui Liu
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

9.  Superoxide radicals have a protective role during H2O2 stress.

Authors:  Geoffrey W Thorpe; Mayfebelle Reodica; Michael J Davies; Gino Heeren; Stefanie Jarolim; Bethany Pillay; Michael Breitenbach; Vincent J Higgins; Ian W Dawes
Journal:  Mol Biol Cell       Date:  2013-07-17       Impact factor: 4.138

10.  Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.

Authors:  Jason J Lohmueller; Shuji Sato; Lana Popova; Isabel M Chu; Meghan A Tucker; Roberto Barberena; Gregory M Innocenti; Mare Cudic; James D Ham; Wan Cheung Cheung; Roberto D Polakiewicz; Olivera J Finn
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

View more
  4 in total

Review 1.  Tumor microenvironment antigens.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2022-09-29       Impact factor: 11.759

Review 2.  Beneficial autoimmunity improves cancer prognosis.

Authors:  Laurence Zitvogel; Claude Perreault; Olivera J Finn; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2021-05-11       Impact factor: 65.011

3.  LCVM infection generates tumor antigen-specific immunity and inhibits growth of nonviral tumors.

Authors:  Camille Jacqueline; Matthew Dracz; Jia Xue; Robert J Binder; Jonathan Minden; Olivera Finn
Journal:  Oncoimmunology       Date:  2022-01-21       Impact factor: 7.723

4.  A novel rat model of vertebral inflammation-induced intervertebral disc degeneration mediated by activating cGAS/STING molecular pathway.

Authors:  Qihang Su; Qiuchen Cai; Yongchao Li; Hengan Ge; Yuanzhen Zhang; Yi Zhang; Jun Tan; Jie Li; Biao Cheng; Yan Zhang
Journal:  J Cell Mol Med       Date:  2021-09-03       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.